TCGA-CU-A3KJ-01A-11R-A21D-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.46254928
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.510
- G2M_CHECKPOINT+0.440
- MITOTIC_SPINDLE+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.360
- E2F_TARGETS+0.330
- SPERMATOGENESIS+0.300
- HYPOXIA+0.280
- IL6_JAK_STAT3_SIGNALING+0.280
- PI3K_AKT_MTOR_SIGNALING+0.280
Top 10 suppressed
- MYOGENESIS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- BILE_ACID_METABOLISM-0.270
- DNA_REPAIR-0.210
- XENOBIOTIC_METABOLISM-0.200
- FATTY_ACID_METABOLISM-0.190
- PEROXISOME-0.190
- ADIPOGENESIS-0.170
- ESTROGEN_RESPONSE_EARLY-0.140
- KRAS_SIGNALING_DN-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290909 | — | — | 0.783 |
| 2 | MNG638 | — | — | 0.780 |
| 3 | TCGA-CU-A0YN-01A-21R-A10U-07 | — | — | 0.771 |
| 4 | TCGA-D8-A1J8-01A-11R-A13Q-07 | — | B | 0.769 |
| 5 | TCGA-A2-A1G1-01A-21R-A13Q-07 | — | E | 0.757 |
| 6 | TCGA-GC-A3RC-01A-11R-A22U-07 | — | — | 0.755 |
| 7 | MNG1210 | — | — | 0.750 |
| 8 | TCGA-G2-A2EJ-01A-11R-A180-07 | — | — | 0.746 |
| 9 | MDT-AP-3281 | Med | Medulloblastoma | 0.745 |
| 10 | SRR650195 | — | — | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |